193 related articles for article (PubMed ID: 34080093)
1. Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.
Saini G; Gogineni K; Kittles RA; Aneja R
Breast Cancer Res Treat; 2021 Jun; 187(3):605-611. PubMed ID: 34080093
[TBL] [Abstract][Full Text] [Related]
2. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.
Abijo T; Blum K; Gondré-Lewis MC
Curr Neuropharmacol; 2020; 18(7):578-595. PubMed ID: 31744450
[TBL] [Abstract][Full Text] [Related]
3. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.
Aldrighetti CM; Niemierko A; Van Allen E; Willers H; Kamran SC
JAMA Netw Open; 2021 Nov; 4(11):e2133205. PubMed ID: 34748007
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life and care satisfaction outcomes: Informing psychosocial oncology care among Latina and African-American young breast cancer survivors.
Ashing KT; George M; Jones V
Psychooncology; 2018 Apr; 27(4):1213-1220. PubMed ID: 29370454
[TBL] [Abstract][Full Text] [Related]
5. An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials.
Markman M; Petersen J; Montgomery R
J Cancer Res Clin Oncol; 2008 Jan; 134(1):115-8. PubMed ID: 17598129
[TBL] [Abstract][Full Text] [Related]
6. Cartographic Mapping and Travel Burden to Assess and Develop Strategies to Improve Minority Access to National Cancer Clinical Trials.
Bruner DW; Pugh SL; Yeager KA; Bruner J; Curran W
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):702-9. PubMed ID: 26281827
[TBL] [Abstract][Full Text] [Related]
7. Increasing accrual of minority patients in breast cancer clinical trials.
Trant AA; Walz L; Allen W; DeJesus J; Hatzis C; Silber A
Breast Cancer Res Treat; 2020 Nov; 184(2):499-505. PubMed ID: 32840699
[TBL] [Abstract][Full Text] [Related]
8. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.
Hirko KA; Rocque G; Reasor E; Taye A; Daly A; Cutress RI; Copson ER; Lee DW; Lee KH; Im SA; Park YH
BMC Med; 2022 Feb; 20(1):72. PubMed ID: 35151316
[TBL] [Abstract][Full Text] [Related]
9. Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers.
Grette KV; White AL; Awad EK; Scalici JM; Young-Pierce J; Rocconi RP; Jones NL
Int J Gynecol Cancer; 2021 Nov; 31(11):1403-1407. PubMed ID: 34088749
[TBL] [Abstract][Full Text] [Related]
10. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
[TBL] [Abstract][Full Text] [Related]
11. Adapting a program to inform African American and Hispanic American women about cancer clinical trials.
Sadler GR; Gonzalez J; Mumman M; Cullen L; Lahousse SF; Malcarne V; Conde V; Riley N
J Cancer Educ; 2010 Jun; 25(2):142-5. PubMed ID: 20146043
[TBL] [Abstract][Full Text] [Related]
12. Barriers to minority participation in breast carcinoma prevention trials.
Grann VR; Jacobson JS; Troxel AB; Hershman D; Karp J; Myers C; Neugut AI
Cancer; 2005 Jul; 104(2):374-9. PubMed ID: 15937913
[TBL] [Abstract][Full Text] [Related]
13. Can Precision Medicine Actually Help People Like Me? African American and Hispanic Perspectives on the Benefits and Barriers of Precision Medicine.
Yeh VM; Bergner EM; Bruce MA; Kripalani S; Mitrani VB; Ogunsola TA; Wilkins CH; Griffith DM
Ethn Dis; 2020; 30(Suppl 1):149-158. PubMed ID: 32269456
[TBL] [Abstract][Full Text] [Related]
14. Genetic ancestry and lower extremity peripheral artery disease in the Multi-Ethnic Study of Atherosclerosis.
Allison MA; Peralta CA; Wassel CL; Aboyans V; Arnett DK; Cushman M; Eng J; Ix J; Rich SS; Criqui MH
Vasc Med; 2010 Oct; 15(5):351-9. PubMed ID: 20926494
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
John EM; Miron A; Gong G; Phipps AI; Felberg A; Li FP; West DW; Whittemore AS
JAMA; 2007 Dec; 298(24):2869-76. PubMed ID: 18159056
[TBL] [Abstract][Full Text] [Related]
16. Barriers to eligibility and enrollment among older women in a clinical trial on osteoporosis: effects of ethnicity and SES.
Unson CG; Ohannessian C; Kenyon L; Case A; Reisine S; Prestwood K
J Aging Health; 2004 Jun; 16(3):426-43. PubMed ID: 15155070
[TBL] [Abstract][Full Text] [Related]
17. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.
Tejeda HA; Green SB; Trimble EL; Ford L; High JL; Ungerleider RS; Friedman MA; Brawley OW
J Natl Cancer Inst; 1996 Jun; 88(12):812-6. PubMed ID: 8637047
[TBL] [Abstract][Full Text] [Related]
18. Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics.
Nahleh Z; Otoukesh S; Mirshahidi HR; Nguyen AL; Nagaraj G; Botrus G; Badri N; Diab N; Alvarado A; Sanchez LA; Dwivedi AK
Cancer Med; 2018 Jun; 7(6):2710-2717. PubMed ID: 29733543
[TBL] [Abstract][Full Text] [Related]
19. Genetic ancestry, self-reported race and ethnicity in African Americans and European Americans in the PCaP cohort.
Sucheston LE; Bensen JT; Xu Z; Singh PK; Preus L; Mohler JL; Su LJ; Fontham ET; Ruiz B; Smith GJ; Taylor JA
PLoS One; 2012; 7(3):e30950. PubMed ID: 22479307
[TBL] [Abstract][Full Text] [Related]
20. Enrollment of women and minorities in NINDS trials.
Burke JF; Brown DL; Lisabeth LD; Sanchez BN; Morgenstern LB
Neurology; 2011 Jan; 76(4):354-60. PubMed ID: 21209376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
